| |
|
|
 |
KP-1461
Koronis is current conducting clinical trials evaluating KP-1461 in HIV patients. Details on ongoing studies can be found at the linked pages below to www.clinicaltrials.gov.
Phase 2a Trial: Ongoing
An Open-label, Multicenter, Mechanism Validation Study to Evaluate the Safety, Efficacy, and Tolerability of KP-1461 as Monotherapy for 124 Days in ARV-experiences, HIV-1-infected Subjects.
More information on joining the Phase 2a Trial of KP-1461
Phase 1b Trial: Enrollment Complete
A Double-Blind, Placebo-Controlled, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of KP-1461 in HIV+ Adults Who Have Failed Two or More Highly Active Antiretroviral Regimens (HAART).
Phase 1a Trial: Enrollment Complete
A Double Blind, Placebo Controlled Dose Escalation Study of the Safety Tolerability, and Pharmacokinetics of a Single Oral Dose of KP-1461 in Normal Healthy Adults
Patients or physicians who would like more information about current clinical trials should contact Koronis
|
|
|
|
|
 |
|
 |
